For the quarter ending 2025-09-30, TERN had $4,732K increase in cash & cash equivalents over the period. -$19,773K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -24,635 | -48,001 |
| Stock-based compensation expense | 3,341 | 6,705 |
| Depreciation expense | 12 | 66 |
| Net accretion on marketable securities | 11 | -135 |
| Change in deferred taxes and uncertain tax positions | -34 | -68 |
| Amortization of right-of-use assets | 99 | 211 |
| Prepaid expenses and other current assets | 1,153 | -524 |
| Accrued interest, net of interest received | -166 | -207 |
| Accounts payable | 97 | 701 |
| Accrued expenses and other liabilities | 2,359 | -3,452 |
| Operating lease liabilities | -104 | -214 |
| Net cash used in operating activities | -19,773 | -43,320 |
| Purchase of property and equipment | 0 | 0 |
| Purchase of marketable securities | 0 | 25,041 |
| Proceeds from maturities of marketable securities | 24,500 | 52,500 |
| Net cash provided by investing activities | 24,500 | 27,459 |
| Net proceeds from the issuance of common stock and pre-funded warrants | 0 | - |
| Payment of deferred offering costs | 0 | 6 |
| Proceeds from stock option exercises | 0 | 146 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 252 |
| Net cash provided by financing activities | 0 | 392 |
| Effect of exchange rate changes on cash and cash equivalents | 5 | -4 |
| Net (decrease) increase in cash and cash equivalents | 4,732 | -15,473 |
| Cash and cash equivalents at beginning of period | 161,439 | - |
| Cash and cash equivalents at end of period | 150,698 | - |
Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. (TERN)